The role of advanced oxidation protein products and total thiols in diabetic retinopathy

European Journal of Ophthalmology

Volumn 18, Issue 5, 2008, Pages 792-798

  Baskol, G ^a   Gumus, K ^a   Oner, A ^a   Arda, H ^a   Karakucuk, Sarper ^a  

^a ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

Author keywords

Advanced oxidation protein products; Diabetic retinopathy; Total thiols

Indexed keywords

ADVANCED OXIDATION PROTEIN PRODUCT; ORAL ANTIDIABETIC AGENT; THIOL;

ADULT; AGE; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETIC RETINOPATHY; DIET RESTRICTION; DISEASE DURATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PATHOGENESIS; PEROXIDATION; PRIORITY JOURNAL; REFRACTION ERROR; SEX DIFFERENCE; STORAGE TEMPERATURE; VENOUS BLOOD;

EID: 54349114292     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.1177/112067210801800521     Document Type: Article

References (31)

1. Ames BN, Shigenaga MK, Hagen TM. Oxidants, antioxidants, and the degenerative diseases of aging. Proc Natl Acad Sci USA 1993; 90: 7915-22.
2. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 1991; 40: 405-12.
3. Armstrong D, al-Awadi F. Lipid peroxidation and retinopathy in streptozotocin-induced diabetes. Free Radic Biol Med 1991; 11: 433-6.
4. Vantyghem MC, Balduyck M, Zerimech F, et al. Oxidative markers in diabetic ketoacidosis. J Endocrinol Invest 2000; 23: 732-6.
5. Caldwell RB, Bartoli M, Behzadian MA, et al. Vascular endothelial growth factor and diabetic retinopathy: role of oxidative stress. Curr Drug Targets 2005; 6: 511-24.
6. Gallou G, Ruelland A, Legras B, Maugendre D, Allanic H, Cloarec L. Plasma malondialdehyde in type I and type II diabetic patients. Clin Chim Acta 1993; 214: 227-34.
7. Li L, Renier G. Activation of nicotinamide adenine dinucleotide phosphate (reduced form) oxidase by advanced glycation end products links oxidative stress to altered retinal vascular endothelial growth factor expression. Metabolism 2006; 55: 1516-23.
8. Losada M, Alio JL. Malondialdehyde serum concentration in type 1 diabetic with and without retinopathy. Doc Ophthalmol 1996-1997; 93: 223-9.
9. Yokoi M, Yamagishi SI, Takeuchi M, et al. Elevations of AGE and vascular endothelial growth factor with decreased total antioxidant status in the vitreous fluid of diabetic patients with retinopathy. Br J Ophthalmol 2005; 89: 673-5.
10. Altomare E, Grattagliano I, Vendemaile G, Micelli-Ferrari T, Signorile A, Cardia L. Oxidative protein damage in human diabetic eye: evidence of a retinal participation. Eur J Clin Invest 1997; 27: 141-7.
11. Martin-Gallan P, Carrascosa A, Gussinye M, Dominguez C. Biomarkers of diabetes associated oxidative stress and antioxidant status in young diabetic patients with or without subclinical complications. Free Radic Biol Med 2003; 34: 1563-74.
12. Cakatay U. Protein oxidation parameters in type 2 diabetic patients with good and poor glycaemic control. Diabetes Metab 2005; 31: 551-7.
13. Piwowar A, Knapik-Kordecka M, Warwas M. AOPP and its relations with selected markers of oxidative/antioxidative system in type 2 diabetes mellitus. Diabetes Res Clin Pract 2007; 77: 188-92.
14. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C, et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996; 49: 1304-13.
15. Hu ML. Measurement of protein thiol groups and glutathione in plasma. Methods Enzymol 1994; 233: 380-5.
16. Jain SK, McVie R. Effect of glycemic control, race (white versus black), and duration of diabetes on reduced glutathione content in erythrocytes of diabetic patients. Metabolism 1994; 43: 306-9.
17. Obrosova IG, Van Huysen C, Fathallah L, Cao XC, Greene DA, Stevens MJ. An aldose reductase inhibitor reverses early diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense. FASEB J 2002; 16: 123-5.
18. Aiello LP. The potential role of PKC beta in diabetic retinopathy and macular edema. Surv Ophthalmol 2002; 47: 263-9.
19. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-20.
20. Curtis TM, Scholfield CN. The role of lipids and protein kinase Cs in the pathogenesis of diabetic retinopathy. Diabetes Metab Res Rev 2004; 20: 28-43.
21. Funatsu H, Yamashita H. Pathophysiology of diabetic retinopathy. Drug News Perspect 2002; 15: 633-9.
22. van Reyk DM, Gillies MC, Davies MJ. The retina: oxidative stress and diabetes. Redox Rep 2003; 8: 187-92.
23. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 1999; 48: 1-9.
24. Haskins K, Bradley B, Powers K, et al. Oxidative stress in Type 1 diabetes. Ann NY Acad Sci 2003; 1005: 43-54.
25. Kowluru RA, Tang J, Kern TS. Abnormalities of retinal metabolism in diabetes and experimental galactosemia. VII. Effect of long-term administration of antioxidants on the development of retinopathy. Diabetes 2001; 50: 1938-42.
26. Wohaieb SA, Godin DV. Alterations in free radical tissue-defense mechanisms in streptozotocin-induced diabetes in rat. Effects of insulin treatment. Diabetes 1987; 36: 1014-8.
27. Aiello LP, Gardner TW, King GE, et al. Diabetic retinopathy. Diabetes Care 1998; 21: 143-56.
28. Gillery P. Advanced glycation end products (AGEs), free radicals and diabetes. J Soc Biol 2001; 195: 387-90.
29. Witko-Sarsat V, Friedlander M, Nguyen-Khoa T, et al. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 1998; 161: 2524-32.
30. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007; 39: 44-84.
31. Telci A, Cakatay U, Salman S, Satman I, Sivas A. Oxidative protein damage in early stage Type 1 diabetic patients. Diabetes Res Clin Pract 2000; 50: 213-23.